Q2 2023
Released Aug 3, 2023, after the close
10-Q filed Aug 3, 2023, 34 days after period end · 0001562762-23-000307
Q2 2023 · 10-Q
Revenue$291.62M$291.62M +10.6% vs Q2 2022+5.4% vs Q1 2023
Net Income$57.71M$57.71M +5.7% vs Q2 2022+17.5% vs Q1 2023
EPS Diluted$0.57$0.57 +7.5% vs Q2 2022+18.7% vs Q1 2023
Gross Profit$215,142,000+10.2%
Operating Income$66,212,000−2.3%
Operating Cash Flowderived$35,028,000−5.0%
Free Cash Flowderived$17,160,000+30.7%
Margins · derived
Gross margin73.8%−0.3 pt vs Q2 2022
Operating margin22.7%−3.0 pt vs Q2 2022
Net margin19.8%−0.9 pt vs Q2 2022
What the release said
The release
Same quarter
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Revenue | $291.62M | $263.65M | $251.02M | $148.92M |
| Net Income | $57.71M | $54.59M | $41.55M | -$20.84M |
| EPS Diluted | $0.57 | $0.53 | $0.40 | -$0.21 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Globus Medical Inc · CIK 1237831 · Engraved from SEC EDGAR